Table 2 Association between breast cancer related lymphoedema and other clinicopathologic variables
BCRL | No BCRL | ||
|---|---|---|---|
(n = 62) | (n = 270) | p-value | |
Side, left n (%) | 41 (66.1) | 130 (48.2) | 0.0106 |
Histological type, n (%) | 0.1734 | ||
NST | 55 (88.7) | 220 (81.5) | |
Others | 7 (11.3) | 50 (18.5) | |
T-staging, n (%)a | 0.5922 | ||
T1 | 39 (62.9) | 157 (58.2) | |
T2 | 19 (30.7) | 80 (29.6) | |
T3 | 2 (3.2) | 10 (3.7) | |
T4 | 2 (3.2) | 23 (8.5) | |
N, n (%)b | 0.1052 | ||
N1 | 33 (53.2) | 176 (65.2) | |
N2 | 13 (21.0) | 53 (19.6) | |
N3 | 16 (25.8) | 41 (15.2) | |
G, n (%)c | 0.6725 | ||
1 | 3 (4.8) | 22 (8.2) | |
2 | 33 (53.2) | 139 (51.5) | |
3 | 26 (41.9) | 109 (40.4) | |
ER positive, n (%) | 53 (85.5) | 241 (89.3) | 0.3998 |
PR positive, n (%) | 49 (79.0) | 226 (83.7) | 0.3791 |
HER2 positive, n (%)d | 9 (14.5) | 22 (8.2) | 0.1202 |
Ki67 positive, n (%)e | 28 (45.2) | 102 (37.8) | 0.2828 |
Molecular subtype, n (%) | 0.6807 | ||
Luminal A | 30 (48.4) | 147 (54.4) | |
Luminal B (HER2+) | 5 (8.1) | 12 (4.4) | |
Luminal B (HER2-) | 18 (29.0) | 82 (30.4) | |
HER2-type | 3 (4.8) | 10 (3.7) | |
Basal | 6 (9.7) | 19 (7.0) | |
ENE, n (%) | 46 (74.2) | 166 (61.5) | 0.0603 |
N. metastatic lymph., median (Q1, Q3) | 3 (1, 7) | 2 (1, 5) | 0.0470 |
Total n. lymph. Evaluated, median (Q1, Q3) | 23 (19, 30) | 23 (18, 29) | 0.4557 |
% lymph. Metastatic, median (Q1, Q3) | 11.1 (5.6, 31.8) | 9.5 (4.5, 25) | 0.2062 |
LVI, n (%) | 29 (46.8) | 80 (29.6) | 0.0095 |